

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**SCHEDULE 14A**

**Proxy Statement Pursuant to Section 14(a) of the  
Securities Exchange Act of 1934  
(Amendment No. )**

Filed by the Registrant   
Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Pursuant to §240.14a-12

**GLOBUS MEDICAL, INC.**  
(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
- Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

- Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

- 

(1) Amount Previously Paid: \_\_\_\_\_

---

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:

---

**Supplement to Definitive Proxy Statement Dated April 28, 2023**

**This Supplement is dated May 2, 2023**

Page 2 of the Definitive Proxy Statement of Globus Medical, Inc. (the “Company”) dated April 28, 2023 (the “Proxy Statement”), as filed with the Securities and Exchange Commission, contained a typographical error in the number of shares of our Class A common stock outstanding as of the record date for our upcoming 2023 Annual Meeting of Stockholders.

We hereby correct the following sentence appearing on page 2 of the Proxy Statement by replacing the incorrect number (79,903,548) with the correct number (77,903,548), such that the sentence shall read: “As of the record date for the Annual Meeting, 77,903,548 shares of our Class A common stock and 22,430,097 shares of our Class B common stock were outstanding.”

---